Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging

• Status: Unknown status
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to assess the use of intranasal dexmedetomidine (IN-dex) as a sole agent in aiding the successful completion of a MRI scans in children. Dexmedetomidine, a routinely used anesthetic agent in our institution, has many benefits including sedation with neuro-protective and respiratory sparing features. We will test its effectiveness in completing MRI scans in children that would otherwise be given a full general anesthetic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Collaborator: British Columbia Children's Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• ASA 1 or 2

• Scheduled for elective MRI scan on the general anesthesia list

• Child Life MRI simulation score of 6-10 (Figure 1)

• Age 3 - 18

Exclusion Criteria:

• Taking existing opioid, sedative, or cannabinoid medication

• Severe learning disability defined as the inability to follow simple commands

• Severe Cardiac disease

• Chronic hypertension

• Allergy to dexmedetomidine

• Nasal anatomical abnormality

• Known or anticipated difficult airway